Transuite.org Inc. Reports Material Agreements & Acquisitions

TL;DR

Transuite.org Inc. filed an 8-K detailing material agreements, asset deals, and equity sales.

AI Summary

Transuite.org Inc. filed an 8-K on October 6, 2025, reporting on several key events. These include entering into a material definitive agreement, the completion of an acquisition or disposition of assets, and unregistered sales of equity securities. The filing also includes financial statements and exhibits related to these events.

Why It Matters

This 8-K filing indicates significant corporate actions by Transuite.org Inc., including potential acquisitions and equity transactions, which could impact the company's structure and future performance.

Risk Assessment

Risk Level: medium — The filing involves material definitive agreements, asset acquisitions/dispositions, and unregistered equity sales, all of which carry inherent risks and potential impacts on the company's financial health and operations.

Key Players & Entities

• TRANSUITE.ORG INC. (company) — Registrant
• October 3, 2025 (date) — Date of earliest event reported
• October 6, 2025 (date) — Date of Report
• Nevada (jurisdiction) — State of incorporation
• 732 S 6th St # 4304 Las Vegas , NV 89101 (address) — Principal Executive Offices

FAQ

Filing Documents

• trso_8k.htm (8-K) — 25KB
• trso_ex101.htm (EX-10.1) — 39KB
• trso_ex991.htm (EX-99.1) — 15KB
• 0001640334-25-001779.txt ( ) — 199KB
• trso-20251003.xsd (EX-101.SCH) — 5KB
• trso-20251003_lab.xml (EX-101.LAB) — 13KB
• trso-20251003_cal.xml (EX-101.CAL) — 1KB
• trso-20251003_pre.xml (EX-101.PRE) — 8KB
• trso-20251003_def.xml (EX-101.DEF) — 2KB
• trso_8k_htm.xml (XML) — 4KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement On September 30, 2025, Transuite.Org Inc. (the "Company" or "TRSO") entered into a Share Exchange Agreement (the "Agreement") with Crestar Holdings Limited, a Hong Kong company ("Crestar"), and Hailiang Li, the shareholder of Xirangsheng (Shenzhen) Health Technology Co., Ltd. ("Seller"). Under the Agreement, TRSO acquires 100% of the outstanding equity securities of Xirangsheng (Shenzhen) Health Technology Co., Ltd. ("XRS") (the "XRS Shares") through Crestar. Business Description : XRS is an innovative enterprise based on the combination of AI Social Agent and Traditional Chinese Medicine ( TCM ) , and is committed to building a complete ecology of "self medical concept+self-medical method+health supervision system". Its vision is to build a self-medical platform for AI Traditional Chinese Medicine to help everyone become their own healthy housekeeper. The company's core products include AI Social Agent based on massive TCM knowledge base, 21-day health supervision system and 300 series of TCM health e-books with independent intellectual property certifications. The company plans to build a fully intelligent e-commerce platform. In the future, the "Super IP Li Ziyi" based on a vast knowledge base of Traditional Chinese Medicine will serve global users in multiple languages through major social platforms such as WeChat and WhatsApp; Transaction Terms: As consideration for the XRS shares, TRSO initially issued ten million (10,000,000) restricted shares of its common stock to Seller. The transaction includes an earnout provision whereby TRSO may issue additional shares based on an independent valuation of XRS to

01 Completion of Acquisition or Disposition of Assets

Item 2.01 Completion of Acquisition or Disposition of Assets On September 30, 2025, TRSO completed the acquisition of 100% of XRS through its subsidiary Crestar. The acquisition was structured as a direct share purchase transaction that closed simultaneously with the execution of the Share Exchange Agreement. The acquisition of XRS represents TRSO's strategic expansion into the AI-powered healthcare technology sector, particularly in the Traditional Chinese Medicine (TCM) market. XRS's core products include AI Social Agents based on massive TCM knowledge bases, health supervision systems, and 300 series of proprietary TCM health e-books with independent intellectual property certifications.

02 Unregistered Sales of Equity Securities

Item 3.02 Unregistered Sales of Equity Securities On September 30, 2025, TRSO issued 10,000,000 shares of restricted common stock to Hailiang Li as initial consideration for the acquisition, in connection with the share exchange transaction described in Items 1.01 and 2.01 above. The issued shares were valued based on TRSO's closing stock price on September 30, 2025, and additional shares TRSO may issue within sixty (60) days after receipt of the independent valuation of XRS upon terms agreed on the Agreement, subject to Board approval and compliance with applicable securities laws.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 10.1 Share Exchange Agreement, dated September 30, 2025, by and among Transuite.Org Inc., Crestar Holdings Limited, and Hailiang Li 99.1 Press Release dated October 3, 2025 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TRANSUTIE.ORG INC. Date: October 6, 2025 By: /s/ Mengqing Fan Name: Mengqing Fan Title: Chief Executive Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR